Elm Street Ventures
VC Fund
New Haven, United States
Elm Street Ventures is a VC fund in New Haven focused on Biotechnology and Health Care. ESVC principal strategy is to create and initially operate life sciences companies founded on intellectual property developed at Yale University and other research institutions in the region (from New York City through Southern New England).With experienced management and access to local, professionally managed venture capital, Elm StreetVentures can help scientists build significant technology companies from the seed and early stage. Our partners include successful serial entrepreneurs and experienced corporate managers, who may serve as the interim CEOs or operating chairmen of a number of the companies we form.While they expect to be co-founders of companies in some circumstances, ESVC are also interested in hearing from entrepreneurs, scientists, and engineers who have already formed or plan to form new ventures in the life sciences.Attractive markets, solid patent protection and freedom to operate, defensible market position, and a world class management team are elements ultimately critical for success.
- Total investments:
- 32
- Last investment:
- Lead investor:
- 13%
- Fund size:
- $30M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Elm Street Ventures invests in
Stages Elm Street Ventures invests in
Countries Elm Street Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Greg Gardiner
|
|||
Brian Dixon
|
|||
|
David R. Whittaker
|
|||
|
Michael Sherman
|
|||
Rob Bettigole
|
|||
| See all 6 contacts → | |||
Investment Focus
Industry
- Biotechnology 13 (41%)
- Health Care 5 (16%)
- Pharmaceutical 5 (16%)
- Medical 4 (13%)
- Biopharma 4 (13%)
Stage
- Series A 11 (34%)
- Seed 6 (19%)
- Funding Round 6 (19%)
- Series B 4 (13%)
- Venture - Series Unknown 2 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Greg Gardiner
Partner
|
Partner | Total investments: 0 | Find email | |
|
Brian Dixon
Venture Partner
|
Venture Partner | Total investments: 1 | Find email | |
|
David R. Whittaker
MD; Venture Consultant
|
MD; Venture Consultant | Total investments: 0 | Find email | |
|
Michael Sherman
Partner
|
Partner | Total investments: 0 | Find email | |
|
Rob Bettigole
Founder & Managing Partner
|
Founder & Managing Partner | Total investments: 2 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
P2 Science
|
P2 Science a venture-backed, renewable specialty chemicals company, co-founded by Yale scientists, a chemical industry CEO and Elm Street Ventures, an early-stage venture fund. P2 Science has developed a unique process technology for converting renewable feedstocks—including vegetable oils—into high-value, specialty chemicals. These includeflavor, fragrance and cosmetics ingredients. Many of their products are today available only from petrochemical sources. Among the first products to be produced by P2 are vegetable-derived, cost-effective versions of current petrochemical fragrance ingredients. Major users and formulators of specialty chemicals have a strong interest in substituting renewable for petrochemical ingredients. Patrick Foley, a Yale graduate of the PhD program in Environmental Engineering, is P2′s Chief Scientific Officer. Neil Burns, an executive with 20+ years experience in the specialty chemical industry, is the company’s CEO. P2 has a laboratory in New Haven, CT to support this technology’s development and commercialization, as well as partnerships with major companies at a number of points along the supply chain. | $23M / May 26, 2026 | |
Halda Therapeutics
|
Halda Therapeutics is a research-stage drug discovery company, seeking to create the next generation of precision medicine based on a novel therapeutic modality which may be a platform for a number of disease states. | $126M / Series B / Aug 12, 2024 | |
EvolveImmune Therapeutics
|
EvolveImmune Therapeutics transforms the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets that are expressed on multiple immune cell types. The company’s platform will generatefirst-in-class treatments for unmet needs in oncology and autoimmune diseases. | $37.4M / Venture - Series Unknown / Nov 16, 2023 | |
CellFE
|
CellFE is a company developing a microfluidics based device to deliver gene-editing molecules. CellFE developed microfluidic device and process that can efficiently deliver gene-editing molecules into the human cells. | $22M / Series A / Sep 27, 2023 | |
|
P2 Science
|
P2 Science a venture-backed, renewable specialty chemicals company, co-founded by Yale scientists, a chemical industry CEO and Elm Street Ventures, an early-stage venture fund. P2 Science has developed a unique process technology for converting renewable feedstocks—including vegetable oils—into high-value, specialty chemicals. These includeflavor, fragrance and cosmetics ingredients. Many of their products are today available only from petrochemical sources. Among the first products to be produced by P2 are vegetable-derived, cost-effective versions of current petrochemical fragrance ingredients. Major users and formulators of specialty chemicals have a strong interest in substituting renewable for petrochemical ingredients. Patrick Foley, a Yale graduate of the PhD program in Environmental Engineering, is P2′s Chief Scientific Officer. Neil Burns, an executive with 20+ years experience in the specialty chemical industry, is the company’s CEO. P2 has a laboratory in New Haven, CT to support this technology’s development and commercialization, as well as partnerships with major companies at a number of points along the supply chain. | Venture - Series Unknown / Feb 23, 2023 | |
Allyx Therapeutics
|
Allyx Therapeutics is a clinical-stage biotechnology company that develops therapies designed to reverse neurodegeneration. Allyx Therapeutics' product is an orally bioavailable small molecule that acts as a silent allosteric modulator, enabling clinicians to get a drug that is capable of delivering a disease-modifying approach and preservecognition in patients. | $7.6M / Jun 01, 2021 | |
|
Allyx Therapeutics
|
Allyx Therapeutics is a clinical-stage biotechnology company that develops therapies designed to reverse neurodegeneration. Allyx Therapeutics' product is an orally bioavailable small molecule that acts as a silent allosteric modulator, enabling clinicians to get a drug that is capable of delivering a disease-modifying approach and preservecognition in patients. | $7.6M / Series A / Jun 01, 2021 | |
Cybrexa Therapeutics
|
Cybrexa Therapeutics is developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale. Our approach will change the paradigm of drug delivery, and itwill greatly enhance the therapeutic index. It has the potential to re-define the definition of “drug-like,” which will unlock a vast array of molecules for clinical development. Our collection of tumor-localizing DNA repair inhibitors can be combined with numerous chemotherapies and also radiotherapy, allowing the safe delivery of higher drug doses, with enhanced efficacy. | $40.2M / Series B / Mar 10, 2021 | |
Artizan Biosciences
|
Artizan Biosciences provides pharmaceutical drug development services, namely, the development of small molecule drugs for use in humans. The Durham-based biotech company declined to disclose its intended use of the proceeds from this offering, as well as its current revenue range. | $18.9M / Series A / Mar 01, 2021 | |
|
P2 Science
|
P2 Science a venture-backed, renewable specialty chemicals company, co-founded by Yale scientists, a chemical industry CEO and Elm Street Ventures, an early-stage venture fund. P2 Science has developed a unique process technology for converting renewable feedstocks—including vegetable oils—into high-value, specialty chemicals. These includeflavor, fragrance and cosmetics ingredients. Many of their products are today available only from petrochemical sources. Among the first products to be produced by P2 are vegetable-derived, cost-effective versions of current petrochemical fragrance ingredients. Major users and formulators of specialty chemicals have a strong interest in substituting renewable for petrochemical ingredients. Patrick Foley, a Yale graduate of the PhD program in Environmental Engineering, is P2′s Chief Scientific Officer. Neil Burns, an executive with 20+ years experience in the specialty chemical industry, is the company’s CEO. P2 has a laboratory in New Haven, CT to support this technology’s development and commercialization, as well as partnerships with major companies at a number of points along the supply chain. | $12M / Series C / Jan 29, 2020 | |
| See all 32 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Elm Street Ventures invest in?
Elm Street Ventures invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series A and Seed stage. Most of the 32 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Elm Street Ventures?
Public channels for Elm Street Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Elm Street Ventures?
The team at Elm Street Ventures includes Greg Gardiner (Partner), Brian Dixon (Venture Partner) and David R. Whittaker (MD; Venture Consultant), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
